Xenetic Biosciences, Inc.

Get Full Access


  • Xenetic Biosciences (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug development platforms include PolyXen, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. Xenetic's lead investigational product candidates include FDA orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also working together with Shire plc (formerly Baxalta, Baxter Incorporated and Baxter Healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on Xenetic's PolyXen technology to conjugate polysialic acid (PSA) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is one of the Company's largest shareholders having invested $10 million in the common stock of the Company during 2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Shire's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100 million plus royalties on sales. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications.
  • location

    Headquarters:40 Speen Street Suite 102, Framingham, Massachusetts, United States

  • Xenetic Biosciences, Inc. phone

    Phone Number: +1 781-778-7720

  • Xenetic Biosciences, Inc. website

    Website: https://www.xeneticbio.com

  • Xenetic Biosciences, Inc. employees


  • Xenetic Biosciences, Inc. revenue

    Revenue:$1 - 10M

  • Xenetic Biosciences, Inc. legal name

    Legal Name:Xenetic Biosciences, Inc.

  • Xenetic Biosciences, Inc.'s Social Media

    Xenetic Biosciences, Inc. linkedin Xenetic Biosciences, Inc. facebook Xenetic Biosciences, Inc. twitter
  • done Is this data correct?
  • |  NAICS Code: 541713  |

    Show More
Person level website identification

CEO for Xenetic Biosciences, Inc.

Scott Maguire

Chief Executive Officer

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Jeffrey Eisenberg

Life Sciences Leader And Board Member

Frequently Asked Questions regarding Xenetic Biosciences, Inc.

  • Where are Xenetic Biosciences, Inc.'s Headquarters?

    Xenetic Biosciences, Inc.'s Headquarters are in 40 Speen Street Suite 102,Framingham,Massachusetts,United States

  • What is Xenetic Biosciences, Inc.'s phone number?

    Xenetic Biosciences, Inc.'s phone number is +1 781-778-7720

  • What is Xenetic Biosciences, Inc.'s official website?

    Xenetic Biosciences, Inc.'s official website is https://www.xeneticbio.com

  • What is Xenetic Biosciences, Inc.'s Revenue?

    Xenetic Biosciences, Inc.'s revenue is $1 - 10M

  • What is Xenetic Biosciences, Inc.'s NAICS code?

    Xenetic Biosciences, Inc.'s NAICS code is 541713

  • How many employees are working in Xenetic Biosciences, Inc.

    Xenetic Biosciences, Inc. has 8 employees

  • What is Xenetic Biosciences, Inc.'s Industry?

    Xenetic Biosciences, Inc. is in the industry of Biotechnology

  • Who is Xenetic Biosciences, Inc.'s CEO?

    Xenetic Biosciences, Inc.'s CEO is Scott Maguire

Company Directory